Sichan Li

Mrs. Sichan Li

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
SLSichan Li
Sichan Li
QYQi Ye
Qi Ye
HXHua Xu
Hua Xu
LZLong Zhang
Long Zhang
YWYang Wang
Yang Wang
Linezolid is a synthetic antibiotic very effective in the treatment of infections caused by Gram-positive pathogens. Although the clinical application of linezolid in children has increased progressively, data on linezolid pharmacokinetics in pediatric patients are very limited.

30 January 2022 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SLSichan Li
Sichan Li
MZMin Zhan
Min Zhan
SWSanLan Wu
SanLan Wu
JLJianXiang Liao
JianXiang Liao
HXHua Xu
Hua Xu
YWYang Wang
Yang Wang

22 December 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SLSichan Li
Sichan Li
YWYueFei Wang
YueFei Wang
HDHui Dong
Hui Dong
YZYuan Zhu
Yuan Zhu
PCPeng Cao
Peng Cao
YWYang Wang
Yang Wang

4 April 2024 in Epilepsia
Verified
Journal Article
Closed access
SLSichan Li
Sichan Li
JYJiaqin Yi
Jiaqin Yi
YTYaLi Tuo
YaLi Tuo
GNGang Nie
Gang Nie
JWJun Wang
Jun Wang
ZLZhisheng Liu
Zhisheng Liu

11 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YWYang Wang
Yang Wang
DSDan Sun
Dan Sun
YMYan Mei
Yan Mei
SWSan-Lan Wu
San-Lan Wu
XLXinlin Li
Xinlin Li
YTYali Tuo
Yali Tuo
The present study aimed to establish population pharmacokinetic models of latamoxef, as well as its R- and S-epimers, and generate findings to guide the individualized administration of latamoxef in pediatric patients. A total of 145 in-hospital children aged 0.08–10.58 years old were included in this study. Three population pharmacokinetic models of latamoxef and its R- and S-epimers were established. The stability and predictive ability of the final models were evaluated by utilizing goodness-of-fit plots, nonparametric bootstrapping, and normalized prediction distribution errors. The final model of total latamoxef was considered as a basis for the dosing regimen. A two-compartment model with first-order elimination best described the pharmacokinetics of total latamoxef. The population typical values of total latamoxef were as follows: central compartment distribution volume (V1) of 4.84 L, peripheral compartment distribution volume (V2) of 16.18 L, clearance (CL) of 1.00 L/h, and inter-compartmental clearance (Q) of 0.97 L/h. Moreover, R-epimer has a higher apparent volume of distribution and lower clearance than S-epimer. Body surface area (BSA) was identified as the most significant covariate to V, CL, and Q. Specific recommendations are given for dosage adjustment in pediatric patients based on BSA. This study highlights that a BSA-normalized dose of latamoxef was required when treating different bacteria to reach the therapeutic target more effectively.

24 October 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SLSichan Li
Sichan Li
MCMing Cao
Ming Cao
YZYan Zhou
Yan Zhou
CSChang Shu
Chang Shu
YWYang Wang
Yang Wang
Ornidazole is frequently used for the prevention and treatment of anaerobic infections after caesarean section. There is still a lack of data on the excretion of ornidazole in breast milk. Therefore, the aim of this study was to investigate the transfer of ornidazole into colostrum and to assess the risk of infant exposure to the drug via breast milk. Population pharmacokinetic analysis was conducted using datasets of plasma and milk concentrations obtained from 77 breastfeeding women to examine the excretion kinetics of ornidazole. Various factors that may affect the excretion of ornidazole were investigated. The final model was then used to simulate ornidazole concentration–time profiles in both plasma and milk. The drug exposure in body fluids and the potential risk for breastfeeding were assessed based on the safety threshold. Plasma ornidazole concentration data could be described well by a one-compartment model, and concentrations in breast milk were linked to this model using an estimated milk-to-plasma concentration ratio (MPRcon). Significant variables that influenced drug exposure and MPRcon were identified as total bilirubin levels (TBIL) and postnatal sampling time, respectively. Simulations showed that women with abnormal liver function (TBIL > 17 μmol/L) had higher ornidazole levels in plasma and milk than those with normal liver function (TBIL < 17 μmol/L), but the exposures through colostrum of lactating women from both groups were below the safety threshold. This work provides a simple and feasible strategy for the prediction of drug exposure in breast milk and the assessment of breastfeeding safety.